A Randomized, Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Trial Profile

A Randomized, Phase 2, Open-Label, Multicenter Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)

Recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Feb 2018

At a glance

  • Drugs KD 025 (Primary)
  • Indications Idiopathic pulmonary fibrosis
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors Kadmon Corporation
  • Most Recent Events

    • 12 Feb 2018 According to a Kadmon Corporation media release, results (n=29) will be presented at the American Thoracic Society (ATS) International Conference in May 2018.
    • 12 Feb 2018 According to a Kadmon Corporation media release, Kevin F. Gibson, MD, Professor and Medical Director, Dorothy P. and Richard P. Simmons Center for Interstitial Lung Disease is the lead investigator of the study.
    • 12 Feb 2018 Results (n=29) are published in the Kadmon Corporation media release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top